We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

75 hedge funds and large institutions have $689M invested in Lyell Immunopharma in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

8,620% more call options, than puts

Call options by funds: $3.92M | Put options by funds: $45K

37% more capital invested

Capital invested by funds: $503M → $689M (+$186M)

37% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 19

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

0.08% more ownership

Funds ownership: 2.07% → 2.15% (+0.08%)

5% less funds holding

Funds holding: 79 → 75 (-4)

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

Holders
75
Holders Change
-4
Holders Change %
-5.06%
% of All Funds
1.26%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
14
Increased
26
Reduced
19
Closed
16
Calls
$3.92M
Puts
$45K
Net Calls
+$3.88M
Net Calls Change
+$925K

Top Buyers

1
BlackRock
BlackRock
New York
+$11.2M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$9.46M
3
MCMU
MIC Capital Management (UK)
United Kingdom
+$8.89M
4
State Street
State Street
Massachusetts
+$3.6M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.16M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$1.42M
2
AP
Adero Partners
California
-$1.28M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.26M
4
WP
Woodline Partners
California
-$1.02M
5
Victory Capital Management
Victory Capital Management
Texas
-$866K
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
76
Woodline Partners
California
– -$1.02M -10,090 Closed
Walleye Capital
77
Walleye Capital
New York
– -$813K -8,047 Closed
Balyasny Asset Management
78
Balyasny Asset Management
Illinois
– -$342K -3,388 Closed
CSS
79
Cubist Systematic Strategies
Connecticut
– -$246K -2,440 Closed
GCP
80
GSA Capital Partners
United Kingdom
– -$237K -2,350 Closed
Susquehanna International Group
81
Susquehanna International Group
Pennsylvania
– -$223K -2,213 Closed
VF
82
Virtu Financial
New York
– -$188K -1,860 Closed
PHK
83
Point72 Hong Kong
Hong Kong
– -$68K -675 Closed
CIBC Asset Management
84
CIBC Asset Management
Ontario, Canada
– -$53K -526 Closed
DTL
85
Dynamic Technology Lab
Singapore
– -$52K -520 Closed
PCG
86
Private Capital Group
Connecticut
– -$1K -13 Closed
MPWT
87
MassMutual Private Wealth & Trust
Connecticut
– -$1K -7 Closed
C
88
Covestor
United Kingdom
– +$204 +2 New
PNC Financial Services Group
89
PNC Financial Services Group
Pennsylvania
– +$204 +2 New
CS
90
Credit Suisse
Switzerland
– +$307 +3 New
1 2 3
4

LYEL Hedge Fund Activity: Q2 2022 in Review

75 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q2 2022, worth a combined $689M — up 37% from $503M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of LYEL and 14 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 26 added.

The largest buyer was BlackRock, adding an estimated $11.2M. The largest seller was Millennium Management, exiting entirely with an estimated $1.42M sold.

  • 75 institutional investors held Lyell Immunopharma (LYEL) as of Q2 2022, down from 79 in Q1 2022.
  • Funds reported $689M of Lyell Immunopharma stock for Q2 2022, up 37% quarter-over-quarter.
  • 14 funds opened new Lyell Immunopharma positions in Q2 2022 and 16 closed out, a net change of -2 holders.
  • The largest Lyell Immunopharma buyer in Q2 2022 was BlackRock, an estimated $11.2M added.
  • The largest Lyell Immunopharma seller in Q2 2022 was Millennium Management, an estimated $1.42M sold.

Based on aggregated 13F filings for Q2 2022.